PF06650833

SIGMA/PZ0327 - ≥98% (HPLC)

Synonym: 1-[[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxo-2-pyrrolidinyl]methoxy]-7-methoxy-6-isoquinolinecarboxamide; PF-06650833

CAS Number: 1817626-54-2
Empirical Formula (Hill Notation): C₁₈H₂₀FN₃O₄
Molecular Weight: 361.37
Linear Formula: C₁₈H₂₀FN₃O₄
Product Type: Chemical

assay	≥98% (HPLC)
color	white to beige
form	powder
InChI	1S/C18H20FN3O4/c1-3-10-13(22-17(24)15(10)19)8-26-18-11-7-14(25-2)12(16(20)23)6-9(11)4-5-21-18/h4-7,10,13,15H,3,8H2,1-2H3,(H2,20,23)(H,22,24)/t10-,13+,15-/m0/s1
InChI key	JKDGKIBAOAFRPJ-ZBINZKHDSA-N
Quality Level	100
SMILES string	NC(C1=C(OC)C=C2C(C=CN=C2OC[C@@H]3[C@H](CC)[C@H](F)C(N3)=O)=C1)=O
solubility	DMSO: 20 mg/mL, clear
storage temp.	room temp

Biochem/physiol Actions:	PF06650833 has been studied for its use in the treatment of Waldenstrom macroglobulinemia, indicated by overproduction of IgM (immunoglobulin M)-producing lymphoplasmacytic cells.
Biochem/physiol Actions:	PF06650833 is an inhibitor of Interleukin-1 receptor associated kinase 4 (IRAK4). IRAK4 kinase is important in innate immunity, involved in initiating signaling from Toll-like receptors and members of th einterleukin-1 receptor family. IRAK4 kinase is an attractive target for the treatment of various diseases associated with deregulated inflammation, such as rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, and systemic lupus erythematosus. PF06650833 has been investigated for treatment of lupus.
Packaging:	5 mg in glass bottle

Symbol	GHS07
Signal word	Warning
Hazard statements	H315 - H319 - H335
Precautionary statements	P305 + P351 + P338
RIDADR	NONH for all modes of transport
WGK Germany	WGK 3
Flash Point(F)	Not applicable
Flash Point(C)	Not applicable